• BIVDA members area

Members' Press Releases

From the monthly archives: October, 2013

We are pleased to present below all posts archived in 'October, 2013'. If you still can't find what you are looking for, try using the search box.

Proteome Sciences Appoints Director of Personalised Medicine

29th October 2013, Cobham, UK: Proteome Sciences plc (“Proteome Sciences”) is pleased to announce it has appointed Dr Chee Gee See as Director of Personalised Medicine with immediate effect.

Read the rest of entry »

End-of-year savings to be made on DiaSorin Blood DNA extraction kits for molecular confirmation of genetic disorders

The DiaSorin Arrow™ Blood DNA 200 extraction assays, that provide a highly purified DNA preparation, reduce inhibition in downstream analysis and ensure accurate and sensitive confirmation of Factor V Leiden thrombophilia, cystic fibrosis and other genetic disorders, are now available from approved DiaSorin distributors at special end-of-year rates.

Read the rest of entry »

Siemens Healthcare Diagnostics enhances allergy testing repertoire

Siemens Healthcare Diagnostics, a global leader in laboratory and clinical diagnostics, has introduced 14 new allergens in addition to two new panels to the 3gAllergy™ allergen menu on the IMMULITE® 2000 and IMMULITE 2000 XPi immunoassay systems. The latest extension means the menu will now offer over 480 individual allergens.

Read the rest of entry »

Improve detection of ‘Winter Bugs’ with DiaSorin nucleic acid extraction kits

DiaSorin LIAISON® Ixt / Arrow BUGS’n BEADS™ extraction kits provide high yield, high purity nucleic acid preparations for sensitive and accurate molecular identification of norovirus and Mycoplasma pneumonia.

Read the rest of entry »

New molecular test aids diagnosis of Toxoplasmosis in pregnancy

The molecular division of DiaSorin, has further strengthened its diagnostic portfolio supporting the health and wellbeing of mothers and babies with the launch of the Iam Toxo assay for the detection of Toxoplasma gondii (T. gondii).

Read the rest of entry »